The mechanism may be related to the down-regulation of LXRα/SREBP-1c/FAS/ACC and SREBP2/HMGCR signaling pathways, which may provide a theoretical basis for the prevention and treatment of hyperlipidemia. The gene discussed is SREBF2; the disease is hyperlipidemia.